Summit Therapeutics plc Share Price London S.E.
Stocks
GB00BN40HZ01
Biotechnology & Medical Research
| Market Cap | 8.82B 11.84B 10.35B 9.55B 16.74B 1,129B 17.02B 114B 44.81B 556B 44.44B 43.48B 1,912B | P/E 2026 * |
-13.4x | P/E 2027 * | -13.5x |
|---|---|---|---|---|---|
| Enterprise Value | 8.56B 11.49B 10.05B 9.27B 16.24B 1,095B 16.51B 111B 43.48B 540B 43.12B 42.19B 1,855B | EV / Sales 2026 * |
3,497x | EV / Sales 2027 * | 210x |
| Free-Float |
16.86% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Summit Therapeutics plc
| Manager | Title | Age | Since |
|---|---|---|---|
Mahkam Zanganeh
CEO | Chief Executive Officer | 54 | 24/07/2022 |
Robert Duggan
CEO | Chief Executive Officer | 81 | 31/03/2020 |
| Director of Finance/CFO | 48 | 01/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Duggan
CHM | Chairman | 81 | 31/01/2020 |
| Director/Board Member | 48 | 30/11/2019 | |
Mahkam Zanganeh
BRD | Director/Board Member | 54 | 10/11/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -2.38% | - | - | 11.84B | |
| -4.14% | -8.06% | +57.35% | +117.24% | 54.63B | |
| +1.84% | -0.66% | +75.79% | +93.87% | 54.88B | |
| -2.24% | +3.59% | +19.60% | +466.72% | 25.06B | |
| -1.60% | -6.21% | -19.69% | -14.84% | 23.14B | |
| +2.43% | +1.06% | +47.70% | -0.11% | 19.88B | |
| -3.19% | 0.00% | +33.99% | -26.87% | 17.55B | |
| -6.84% | +2.18% | +195.12% | +357.18% | 16.5B | |
| -1.05% | +1.16% | +25.08% | +196.28% | 14.2B | |
| +8.74% | +3.51% | +53.81% | - | 15.36B | |
| Average | -0.61% | -0.28% | +54.31% | +148.68% | 26.8B | |
| Weighted average by Cap. | -0.87% | -1.46% | +55.04% | +137.79% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.45M 3.28M 2.87M 2.65M 4.64M 313M 4.72M 31.66M 12.43M 154M 12.33M 12.06M 531M | 42.03M 56.41M 49.34M 45.51M 79.76M 5.38B 81.1M 544M 214M 2.65B 212M 207M 9.11B |
| Net income | -657M -882M -772M -712M -1.25B -84.14B -1.27B -8.5B -3.34B -41.45B -3.31B -3.24B -142B | -680M -913M -799M -737M -1.29B -87.08B -1.31B -8.8B -3.46B -42.9B -3.43B -3.35B -147B |
| Net Debt | -262M -351M -307M -283M -497M -33.5B -505M -3.39B -1.33B -16.5B -1.32B -1.29B -56.73B | -11.05M -14.83M -12.97M -11.96M -20.97M -1.41B -21.32M -143M -56.13M -697M -55.67M -54.46M -2.39B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
